Oncology

BioAesthetics Announces a $5M Series A to Commercialize NACgraft, a Regenerative Nipple Graft for Breast Cancer Survivors

BioAesthetics Corporation today announced that it has doubled its initial Series A funding goal of $2.5 million, closed on Dec. 30, 2020, at $5 million to commercialize its NACgraft biologic matrix— a regenerative nipple graft for breast cancer survivors. BioAesthetics’ Series A was co-led by FemHealth Ventures and personally by BioAesthetics’ Director Sandra Coufal, MD, of Sibling Capital Ventures. BioAesthetics’ inaugural product, the NACgraft — for patients…

Roche Launches Two Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer. The uPath image analysis algorithm suite…

Hologic to Acquire Biotheranostics, a Leader in Molecular Tests for Breast and Metastatic Cancers

Hologic announced today that it has agreed to acquire Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments. “Acquiring Biotheranostics enables us to jump-start our entry into a large, fast-growing oncology adjacency that fits perfectly with our broader corporate focus and passion…

Breast Cancer Diagnostics: Hologic Acquires SOMATEX Medical Technologies, A Leader in Biopsy Site Markers and Localization Technologies

Hologic, a medical technology company primarily focused on improving women’s health, announced today it has completed the acquisition of SOMATEX Medical Technologies, a leader in biopsy site markers and localization technologies, for approximately $64 million. The company was previously owned by E-Med Solutions, a group of investors led by German private equity company Westlake Partners. The transaction supports Hologic’s strategy to provide…

Volpara Health Announces Two New Studies to Evaluate the Impact of Their AI-Powered Software in Breast Cancer Risk Assessment

Earlier this week Volpara Health announced two new research studies using their AI-powered software to score breast density objectively and consistently to evaluate its impact in mammography and breast cancer risk assessment. Volpara Density software uses a combination of x-ray physics and machine learning to generate an accurate volumetric measure of breast composition and remains the density measurement tool of choice for…